---

Management of Malignant Pleural Effusion (MPE)

Complete MD Examination Answer (15 Marks)

---

Definition

---

Epidemiology & Prognosis

• Affects approximately 15% of all cancer patients
• Accounts for >125,000 hospitalizations/year in the USA
• Median survival: 3–12 months (ranges 3–11 months depending on primary tumor type; ~5 months overall)
• Presence of MPE denotes advanced-stage/disseminated disease with poor overall prognosis

---

Etiology — Common Primary Malignancies

---

Pathophysiology

1. Lymphatic obstruction — tumour infiltrates lymphatic channels between parietal pleura and mediastinal nodes, reducing reabsorption
2. Increased vascular permeability — plasma leakage through hyperpermeable pleural vasculature (now recognised as the primary driver)
3. VEGF-mediated mechanism — VEGF (from tumour and host cells) is a powerful angiogenic factor and potent stimulator of vascular hyperpermeability; levels are markedly higher in MPE vs. non-malignant effusions
4. Inflammatory cascade — NF-κB and STAT3 transcriptional programs → release of TNF-α, IL-6, CCL2, osteopontin → further effusion formation
5. Direct extension / lymphangitic spread — tumour cells metastasise through pulmonary vasculature → visceral pleura → parietal pleura

---

Clinical Features

• Dyspnea (most common; often disproportionate to effusion size)
• Cough, pleuritic chest pain, weight loss
• Dullness to percussion, reduced breath sounds, tracheal deviation (large effusions)
• Effusion is usually unilateral, moderate-to-large, and recurrent

---

Diagnosis

1. Imaging

• Chest X-ray: blunting of costophrenic angle (>300 mL), opacification, mediastinal shift
• CT chest: pleural nodularity, thickening, loculations, primary tumour identification
• Ultrasound: confirms effusion, guides thoracentesis (preferred guidance modality)

2. Pleural Fluid Analysis

• Exudate by Light's criteria (typically): protein >3 g/dL, LDH elevated, pleural:serum protein >0.5, pleural:serum LDH >0.6 — (can rarely be transudative)
• Glucose: may be reduced (<60 mg/dL) with high tumour burden
• Appearance: often haemorrhagic/blood-tinged
• pH: <7.2 portends poor response to pleurodesis
• Cytology: Diagnosis established in ~60% with one thoracentesis; ~80% with repeat thoracentesis
  • Sensitivity highest for adenocarcinoma (~70%), lower for mesothelioma (<10%), SCC (~20%), lymphoma (25–50%)

3. Pleural Biopsy

• Image-guided (CT/US) needle biopsy of pleural thickening or nodules if cytology negative
• Medical thoracoscopy / VATS: most definitive — allows direct visualisation and targeted biopsy; sensitivity >90% for malignancy. Indicated if cytology remains non-diagnostic and malignancy strongly suspected
• Cell-free DNA from pleural fluid supernatant can detect driver mutations (e.g., EGFR)

---

Management

General Principles

• Management is palliative — goals are symptom relief (especially dyspnea) and minimising repeat invasive procedures
• Asymptomatic effusions — observation acceptable; treat underlying malignancy if responsive
• Before invasive treatment, confirm dyspnea improves after a therapeutic thoracentesis (test drainage)
• Assess for lung re-expansion post-drainage (CXR, pleural manometry) — crucial for deciding treatment strategy

---

Algorithm Based on Lung Expandability

MPE confirmed
    │
    ├─ Asymptomatic ──────────────────► Observe / treat primary malignancy
    │
    └─ Symptomatic
          │
          ├─ Responds to systemic therapy (breast cancer, lymphoma, SCLC)
          │        └──► Chemotherapy/hormone therapy first
          │
          └─ Does not respond / large symptomatic effusion
                    │
                    ├─ SHORT life expectancy / poor performance status
                    │        └──► Repeated therapeutic thoracentesis
                    │
                    └─ LONGER life expectancy / GOOD PS
                              │
                              ├─ EXPANDABLE LUNG
                              │        ├──► Talc pleurodesis (VATS poudrage OR chest tube slurry)
                              │        └──► Indwelling Pleural Catheter (IPC/TPC)
                              │
                              └─ NON-EXPANDABLE "TRAPPED" LUNG
                                       └──► Indwelling Pleural Catheter (IPC) ONLY

---

A. Therapeutic Thoracentesis

• Indication: symptomatic relief in patients with short life expectancy or as a diagnostic step
• Removes 1–1.5 L at a time (limit to avoid re-expansion pulmonary oedema)
• Safe, outpatient procedure under ultrasound guidance
• Limitation: effusion invariably recurs; not definitive for recurrent MPE

---

B. Chemical Pleurodesis

• Lung must be expandable (trapped lung → pleurodesis will fail)
• Pleural fluid pH >7.2 (pH <7.2 → poor response)
• Patient suitable for procedure

Sclerosing Agents (in order of efficacy):

Methods of Pleurodesis:

1. VATS (Video-Assisted Thoracoscopic Surgery) with talc poudrage — preferred: talc aerosolised under direct thoracoscopic vision; allows biopsy simultaneously; highest success rates
2. Chest tube (tube thoracostomy) with talc slurry — bedside; insert 12–14 Fr catheter, drain completely, instil 4 g talc in 50 mL NS, clamp for 1–2 hours, rotate patient, then reopen to suction
3. Mechanical pleurodesis / pleurectomy — reserved for failed chemical pleurodesis with reasonable life expectancy

---

C. Indwelling (Tunnelled) Pleural Catheter (IPC/TPC)

• Non-expandable / trapped lung (pleurodesis will fail)
• Patient preference for outpatient management
• Failed previous pleurodesis
• Pleural loculations
• Limited life expectancy (avoids hospitalisation)
• Poor performance status

• Position: oblique/decubitus with effusion side up
• Ultrasound-guided: two incisions — pleural insertion site + exit site 5–8 cm lateral and caudal
• Catheter tunnelled subcutaneously from caudal-lateral to cranial-medial incision
• Seldinger technique with J-wire and peel-away introducer
• Placed in 6th–7th intercostal space posterolaterally (serratus anterior–latissimus dorsi junction)

• Effective symptom control
• ~50% achieve spontaneous pleurodesis (autopleurodesis) over weeks with daily drainage
• Daily drainage > every-other-day for achieving pleurodesis
• Adding intrapleural talc through IPC further increases pleurodesis rates (LCAT trial)
• Dramatically changed end-stage cancer management — avoids hospitalisation

---

D. Treatment of Underlying Malignancy

• Breast cancer — hormone therapy, chemotherapy
• Small cell lung carcinoma (SCLC) — chemotherapy highly effective
• Lymphoma — chemotherapy ± radiotherapy

---

E. Other / Special Situations

---

Post-Procedure Monitoring

• Chest X-ray after drainage to confirm re-expansion
• Monitor for re-expansion pulmonary oedema (do not drain >1.5 L at a time)
• If lung fails to expand → consider pneumothorax ex vacuo, trapped lung → IPC preferred
• IPC complications: infection (~5%), catheter blockage, tumour seeding (rare), cellulitis

---

Summary Table — Management Options

---

Recent Evidence (2023–2025)

• Intrapleural fibrinolytic therapy for loculated MPE shows benefit in recent systematic review [PMID: 40294877, Crit Rev Oncol Hematol 2025]
• Emerging data on intrapleural immunotherapy (intrapleural bio-products)

---

1. MPE = exudate, blood-tinged, recurrent — always confirm diagnosis via cytology/biopsy before definitive management
2. Lung expandability is the pivotal decision point: expandable → pleurodesis or IPC; trapped lung → IPC only
3. Talc is the best sclerosant (success 60–90%)
4. IPC allows outpatient management and achieves autopleurodesis in ~50%
5. Pleural fluid pH <7.2 → poor pleurodesis response → prefer IPC
6. Management is palliative — goal is quality of life, not cure

---